This review describes how angiotensin AT 1 receptor antagonists (eg, candesartan cilexetil, losartan) effectively protect against end-organ damage including stroke, cardiac hypertrophy, renal dysfunction, glomerulosclerosis, and/or vascular hypertrophy in the models of stroke-prone spontaneously hypertensive rats (SHRSP), SHR, DOCA/salt hypertensive rats, Dahl hypertensive rats and/or 5/6 nephrectomised rats. Particularly in SHRSP and DOCA/salt hypertensive rats, candesartan cilexetil markedly reduced the incidence of stroke and renal injury even at doses which had no effect on blood pressure (BP), suggesting that the tissue protective effects of angiotensin AT 1 antagonists are not attributable simply to the normalisation of BP. In the heart, kidney and vascular tissues of SHRSP and the kidney of DOCA/salt hypertensive rats, the mRNA
Introduction
There are a number of angiotensin AT 1 receptor antagonists available or in the late stages of development ( Figure 1 ). The introduction of the angiotensin AT 1 receptor antagonist has made it possible to examine the pathophysiological role of angiotensin AT 1 receptors in cardiovascular diseases. Angiotensin AT 1 receptor stimulation not only causes hypertension, but also seems to be involved in the development of cardiovascular end-organ damage seen in the form of stroke, congestive heart failure, cardiac hypertrophy, renal dysfunction, glomerulosclerosis, vascular wall proliferation, and so on. Angiotensin AT 1 receptor stimulation has haemodynamic effects mainly due to vasoconstrictor action. In addition, increasing evidence suggests that its stimulation also has a direct pathophysiological effect on target tissues, which include the brain, heart, kidney and vascular wall. The combined effects of haemodynamic and direct pathophysiological actions may be responsible for the initiation and progression of endorgan damage.
This review is focused on the findings of in vitro and in vivo pharmacological studies that strongly suggest that angiotensin AT 1 receptor antagonists Correspondence: Dr K Nishikawa, Pharmaceutical Research Division, Takeda Chemical Industries Ltd, 2-17-85 Juso-Honmachi, Yodogawa-ku, Osaka 532, Japan levels for transforming growth factor (TGF)-␤1 and extracellular matrix components (fibronectin, collagen type I, III and IV and laminin) were increased, and the increases of the gene expression were inhibited by treatment with candesartan cilexetil. In addition, there are some reports indicating that angiotensin AT 1 receptor antagonists inhibit directly hypertrophy or proliferation of cultured cardiac myocytes and nonmyocytes (fibroblast), cultured mesangial cells and cultured vascular smooth muscle cells, which were stimulated by angiotensin II. These in vitro and in vivo findings suggest that local tissue AT 1 receptor stimulation, being accompanied by the increased gene expression of TGF-␤1 and extracellular matrix components may partially contribute to the pathogenesis of cardiovascular endorgan damage.
can provide effective protection against end-organ damage. Candesartan cilexetil used in this review is a highly potent and long acting angiotensin AT 1 receptor antagonist.
1,2 The protective effects of candesartan cilexetil against end-organ damage, which have been observed in the models of stroke-prone spontaneously hypertensive rats (SHRSP), [3] [4] [5] deoxycorticosterone acetate (DOCA)/salt hypertensive rats 6,7 and 5/6 nephrectomised rats 8 are described.
Materials and methods

Stroke-prone spontaneously hypertensive rats (SHRSP)
Male SHRSP, aged 19 to 27 weeks, and age-matched male Wistar-Kyoto (WKY) rats were used. 3 Candesartan cilexetil at dosages of 0.1, 1 and 10 mg/kg was administered to the rats by gavage once daily for 10 weeks. Control rats were given the corresponding vehicle only. Systolic blood pressure (SBP) was measured by the tail-cuff method just before and 5 h after administration at the end of the 1st and 2nd week, and every 2 weeks thereafter. Rats were observed for signs of stroke throughout the experiment. The stroke incidence was assessed by observing for behavioural abnormalities such as twitch, paralysis, convulsions and loss of the righting and postural reflexes and reduced body weight gain. left and right ventricles at the end of the experiment. Kidney dysfunction was assessed by measuring the urinary excretion of albumin and histological examination. At the end of the 10th week of medication, spontaneous urine of the rats was collected for 24 h in separate metabolic cages with free access to water but not food. At the end of the experiment the rats were decapitated and the heart, kidney, superior mesenteric artery and thoracic aorta were excised. The left ventricle, mesenteric artery and aorta were fixed in buffered-glutaraldehyde and embedded in paraffin. Four-m thick sections were cut and stained with haematoxylin and eosin or elastica van Gieson for the estimation of fibrosis. Myocyte width and percent collagen fraction of the left ventricle and the luminal and medial areas of the aorta and mesenteric artery were measured by using an image analyser system. 5 The kidney was fixed in 10% v/v phosphate-buffered formalin, embedded in paraffin, cut into 4-m-thick sections, which were stained with haematoxylin-eosin, and examined microscopically, and the renal lesions were scored according to the following criteria: 0, intact; 1, slight; 2, mild; 3, moderate; and 4, severe. 3, 4 To determine the cellular mechanisms for tissue protective action of candesartan cilexetil, the messenger RNA (mRNA) expression of TGF-␤1 and extracellular matrix components in the interstitium (fibronectin, collagen type I and III) and basement membrane (collagen type VI and laminin) was examined in the left ventricle, whole kidney and vascular tissues. Tissue mRNA was measured by Northern blot analysis with a specific complementary DNA probe. 4 ,5
DOCA/salt hypertensive rats
Male Wistar rats aged 5-6 weeks were uninephrectomised followed by implantation with 25 mg DOCA/pellets and 1% NaCl loading. In sham-operated rats, a dorsal incision was made, but both kidneys were left intact and no DOCA pellet was implanted. 6 The rats were given free access to a standard diet and tap water. SBP was measured 3 weeks after the operation using the tail-cuff method, and the rats with BP Ͼ180 mm Hg were used. Candesartan cilexetil at a dose of 1 mg/kg was orally given once daily to the rats for 3 weeks. BP was measured 5 h after dosing on days 1, 7, 14 and 21 of the dosing period. On a day during week 3 of the dosing period, urine was collected for 24 h immediately after dosing under fasting conditions in metabolic cages. During the urine collection period the rats were given free access to 1% NaCl solution. After the 3-week dosing period the rats were killed by decapitation, and the brain, right kidney, heart and aorta were removed. The kidney was immediately separated into the cortex and medulla, and the cardiac left ventricle was separated from the right ventricle and atria. The renal cortex, left ventricle and aorta were stored at −80°C. One hemisphere of the brain was divided into the cortex, including hippocampus and striatum, and the brain stem, including medulla oblongata, which were stored at −80°C until measurement of w 3 -subtype benzodiazepine binding, which is a marker of cerebrovascular damage. 10 The other hemisphere of the brain and left kidney were fixed in 10% neutral buffer formalin for histo-logical examination. 6, 7 The brain from another series of rats was used for measurement of water and sodium contents. The mRNA levels for TGF-␤1 and extracellular matrix components in the interstitium and basement membrane in the renal cortex, left ventricle and aorta were also examined. 4 ,5,7
5/6 nephrectomised rats
Male Sprague-Dawley rats aged 5 weeks were subjected to 5/6 nephrectomy. 8 Candesartan cilexetil at a dose of 1 mg/kg was orally given once daily to the rats for 16 weeks starting the 15th week after nephrectomy. Vehicle alone was given to the control 5/6 nephrectomised rats and sham-operated rats, respectively. SBP was monitored and urinary albumin was measured as described above. At the end of the experiment, the kidneys from the rats were fixed in 10% neutral buffered formalin and embedded in paraffin. Sections of 4-m in thickness were stained with haematoxylin and eosin, periodic acidmethenamine silver (PAM) and Azan for examination of glomerulosclerosis and tubulointerstitial lesions. For each rat, the number of glomeruli with segment lesions was expressed as a percentage of the total number of glomeruli counted. The expression of TGF-␤1 in glomeruli was examined by an immunohistochemical assay. 
Results
Stroke-prone spontaneously hypertensive rats (SHRSP)
The BP of the vehicle-treated SHRSP was 220-230 mm Hg throughout the experimental period which represented severe hypertension. At 10 weeks of treatment, candesartan cilexetil at a dose of 0.1 mg/kg had no significant effect on BP, but at 1 and 10 mg/kg it reduced BP in a dose-related manner ( Figure 2 ). 3 From around the 3rd week of the experiment, the vehicle-treated SHRSP showed behavioural changes such as twitch, paralysis, convulsions, loss of righting reflexes, loss of postural reflexes and impaired body weight gain. Stroke signs at the end of the treatment were observed in 64% of the vehicle-treated SHRSP and in only 10% of the group treated with 0.1 mg/kg candesartan cilexetil, whereas treatment with 1 and 10 mg/kg candesartan cilexetil did not induce any stroke sign. 3 At the 10th week of treatment, urinary albumin excretion in the vehicle-treated SHRSP increased significantly compared with that of WKY rats. Candesartan cilexetil dose-dependently reduced albumin excretion significantly, even in the group with 0.1 mg/kg, which had no effect on BP. 3 At the end of the experiment, the left ventricular weight of the vehicle-treated SHRSP was significantly higher than that of WKY rats. Treatment with candesartan cilexetil (1 and 10 mg/kg) dose-dependently prevented an increase in the left ventricular weight, but at 0.1 mg/kg it had no significant effect on cardiac hypertrophy. 3 Histological examination showed that left ventricular myocyte width of the vehicle-treated SHRSP (23.3 ± 1.0 m) was larger than that of WKY (19.0 ± 1.0 m) and candesartan cilexetil (10 mg/kg) significantly decreased myocyte width of SHRSP (17.7 ± 1.5 m). 5 Increase in percent collagen fraction in the left ventricle of the vehicle-treated SHRSP also tended to be decreased by treatment with candesartan cilexetil. 5 There were no differences among the right ventricular weights of any of these groups. In the kidney of the vehicle-treated SHRSP, fibrinoid necrosis and capillary atrophy tract were observed in the glomeruli, and atrophy, hypertrophy of the basement membrane, hyaline cast formation and dilatation were observed in renal tubules, and hypertrophy and fibrinoid necrosis were observed in the arterial and arteriolar vascular beds. Candesartan cilexetil reduced the severity of these changes as compared with those of the vehicle-treated SHRSP.
3,4 A non-anti-hypertensive dose of candesartan cilexetil protected the lesions in arteries locally; however, its anti-hypertensive dose (10 mg/kg) protected the lesions of both glomeruli and arterioles. 4 Figures 3 and 4 summarises the mRNA expression for TGF-␤1 and extracellular matrix components in the tissues. 4, 5 In the left ventricle, TGF-␤1 mRNA level tended to increase in the vehicle-treated SHRSP compared with WKY rats and the mRNA levels for fibronectin, collagen type I, III and IV and laminin were increased 2.0-, 2.9-, 2.5-, 1.6-and 2.3-fold, respectively, in the vehicle-treated SHRSP compared with WKY rats. Candesartan cilexetil at doses of 0.1 to 10 mg/kg inhibited the mRNA expression of these components in a dose-related manner, although the inhibitory effect at 0.1 mg/kg was significant in the mRNA expression of fibronectin and laminin. 5 In the whole kidney, the mRNA 5 The white arrow (Ĵ) indicates that the gene expression is significantly increased in SHRSP as compared with WKY. Candesartan cilexetil (1 and 10 mg/kg) markedly inhibited the increase in these gene expressions. , P Ͻ 0.05 and , P Ͻ 0.01, respectively (n = 5). The lower figure shows candesartan cilexetil inhibits (or tends to inhibit) the development of the medial hypertrophy of the aorta and mesenteric artery. ‫ء‬ P Ͻ 0.05 vs SHRSP-vehicle. levels for TGF-␤1, fibronectin, collagen type I, III and IV in the vehicle-treated SHRSP were 3.4-, 5.6-, 4.3-, 2.8-and 2.1-fold, respectively, higher than WKY rats. 4 Candesartan cilexetil at all the doses of 0.1 to 10 mg/kg markedly inhibited the mRNA expression of these components. The mRNA expression for laminin was not different between SHRSP and WKY rats and unaffected by candesartan cilexetil. In the vascular tissues, the mRNA levels for TGF-␤1, fibronectin, collagen type I, III and IV and laminin in the aorta of the vehicle-treated SHRSP were 1.9-, 4.7-, 2.2-, 1.2-, 1.3-and 1.6-fold, respectively, higher than WKY rats, and the mRNA levels for TGF-␤1, fibronectin, collagen type I, III and IV and laminin in the mesenteric artery of the vehicle-treated SHRSP were 2.6-, 9.1-, 2.0-, 2.3-, 1.3-and 1.3-fold, respectively, higher than WKY rats. Candesartan cilexetil at doses of 1 and 10 mg/kg markedly inhibited the mRNA expression of these components. 5 Histological examination showed that candesartan cilexetil significantly prevented the development of the medial hypertrophy of the aorta and tended to prevent the medial hypertrophy of the mesenteric artery (Figure 4) . 5 
DOCA/salt hypertensive rats
As shown in Figure 5 , BP and left ventricular weight were markedly increased in the control-DOCA/salt hypertensive rats as compared with the shamoperated rats. 6, 7 Treatment with candesartan cilexetil for 3 weeks had little effect on BP and left ventricular weight. The urinary albumin level was significantly higher in the control-DOCA/salt hypertensive rats than in the sham-operated rats. 6 Candesartan cilexetil markedly inhibited the increase in the urinary albumin level. Peripheral w 3 -subtype benzodiazepine binding was increased in the cerebral cortex of the control-DOCA/salt hypertensive rats. The binding was 2.3-fold as great as in the sham-operated rats. Candesartan cilexetil markedly inhibited the increase in the benzodiazepine binding. 6 The benzodiazepine binding in the brain stem was also increased, but not significantly. 6 The water content as well as sodium content was significantly increased in the cerebral cortex of the control-DOCA/salt hypertensive rats and candesartan cilexetil inhibited the formation of oedema of the cortex. 6 Histological examination showed that in the cerebral cortex of the control-DOCA/salt hypertensive rats, haemorrhage, fibrinoid necrosis of the arteriole and periarteriolar tissue, and oedema were often observed. In many cases of the control rats granulation of tissues, infiltration of macrophages and a glial reaction were observed, and in the leptomeningeal artery, hyalinised hypertrophy of the intima, inflammation in the periartery and desquamation of the intima were observed. 6 Candesartan cilexetil reduced some of this morphological damage and the oedema in the corpus callosum. Stratified hypertrophy, fibrinoid necrosis and insudation of erythrocytes were observed in many arterioles in the renal cortex in the control-DOCA/salt hypertensive rats. 6 Atrophy of the epithelium, hypertrophy of the basement membrane, dilatation and hyaline casts were observed in the renal tubules. 6, 7 Fibrinoid necrosis and atrophy of the capillary tuft were observed in the glomerulus. Fibrosis and infiltration of lymphocytes were observed in the interstitium. 6, 7 Candesartan cilexetil significantly reduced the damage in the renal tubules, the fibrinoid necrosis in the glomerulus and the interstitial fibrosis. 6, 7 Renal cortical mRNA levels for TGF-␤1 and extracellular matrix components in the interstitium, fibronectin and collagen type I and III, in the control-DOCA/salt hypertensive rats were 2.4-, 3.9-, 4.6-and 3.1-fold higher, respectively, than those in the shamoperated rats. 7 Candesartan cilexetil significantly decreased the increase in these mRNA expressions. Renal cortical mRNA levels for collagen type IV and laminin B1 of basement membrane components in the control-DOCA/salt hypertensive rats were 3.0-and 1.6-fold higher, respectively, than those in the sham-operated rats. Candesartan cilexetil significantly decreased the gene expression of collagen type IV and tended to decrease that of laminin B1. 7 In the aorta of the control-DOCA/salt hypertensive rats, TGF-␤1 and fibronectin mRNA levels were 1.7-and 6.6-fold higher, respectively, than in the shamoperated rats, and collagen type I and III mRNA levels were lower in DOCA/salt hypertensive rats than in the sham-operated rats, but the gene expression of collagen type IV was not altered. 7 In the heart, only fibronectin mRNA was higher in DOCA/salt hypertensive rats than in the sham-operated rats. These mRNA levels in the aorta and heart of DOCA/salt hypertensive rats were not affected by treatment with candesartan cilexetil, 7 suggesting that the expression of these genes is regulated in a tissue-specific manner.
5/6 nephrectomised rats
The 5/6 nephrectomised rats developed systemic hypertension and an increase in urinary albumin excretion. Treatment with 1 mg/kg candesartan cilexetil for 16 weeks inhibited the increase in BP and urinary albumin excretion ( Figure 6 ). 8 Histological examination of the kidney showed prominent glomerulosclerosis and interstitial fibrosis in the vehicle-treated 5/6 nephrectomised rats. Candesartan cilexetil significantly prevented the progression of glomerulosclerosis and interstitial fibrosis. 8 The expression of TGF-␤1 was detected in the injured glomeruli of the vehicle-treated rats, which was markedly inhibited by candesartan cilexetil. 8 
Discussion
The findings shown in this paper indicate that the angiotensin AT 1 receptor antagonist, candesartan cilexetil, can protect against tissue damage, which includes stroke, cardiac hypertrophy, vascular hypertrophy and glomerulosclerosis, in SHRSP, DOCA/salt hypertensive rats and/or 5/6 nephrectomised rats. Particularly candesartan cilexetil (0.1 mg/kg per day) was effective in protection against stroke and renal injury despite not having a significant anti-hypertensive effect (Figures 2 and 5) suggesting that AT 1 receptor antagonists have tissue protective action independent of their BP-lowering action.
Transforming growth factor-␤1 (TGF-␤1) is a multifunctional growth factor and plays an important role in cell proliferation or hypertrophy and synthesis of extracellular matrix components. Candesartan cilexetil inhibited the gene expression of TGF-␤1 and extracellular matrix components which were upregulated in the left ventricle, kidney and vascular tissues of SHRSP and in the kidney of DOCA/salt hypertensive rats, being accompanied by the significant reduction in cardiac hypertrophy, vascular hypertrophy and renal injury. 4, 5, 7 These findings suggest that angiotensin AT 1 receptor antagonists have tissue protective effects by inhibiting the gene expression of these components.
Among the studies done with SHRSP, there are some papers indicating that losartan effectively pro- tects against tissue damage.
11 -15 When losartan at the doses of 1 and 10 mg/kg/day, which afforded none and only moderate anti-hypertensive effects, respectively, was administered to salt-loaded 5-week-old SHRSP for 15 weeks, losartan (1 and 10 mg/kg) completely suppressed stroke and mortality and strongly opposed (1 mg/kg) and abolished (10 mg/kg) the increase in proteinuria observed in the control. 11 Losartan markedly limited (1 mg/kg) or abolished (10 mg/kg) vascular fibrinoid necrosis formation in the brain, kidney and heart. Losartan, especially at 10 mg/kg, reduced arterial thickening and glomerular and tubulo-interstitial lesions in the kidney, as well as arterial thickening, infarction, and fibrosis in the heart. Some of the preventive effects of losartan continued 8 weeks after discontinuation of treatment with losartan. Losartan, most likely independently of its BP-lowering effect, afforded a full and long lasting protection against end-organ damage. 11 Losartan (10 mg/kg/day), when administered to 5-week-old SHRSP for 8 weeks, also suppressed cerebrovascular lesion and cardiac hypertrophy, but hydralazine did not prevent cardiac hypertrophy, although it reduced BP. 12 Losartan (30 mg/kg/day), when administered to 6-weekold saline-loaded SHRSP for 12 weeks, affected renal pathophysiology by blunting the decline in glomerular filtration rate, controlling proteinuria and preventing or delaying the appearance of malignant nephrosclerosis. Losartan increased survival and completely prevented cerebrovascular infarcts. 13 Losartan was also effective in the prevention of stroke at a dose which had no effect on BP.
14 Candesartan (CV-11974) lowered BP in a manner similar to hydralazine, but reduced urinary protein excretion more than hydralazine in SHRSP. 15 The glomerulosclerosis index was greater in non-treated and hydralazine-treated SHRSP than in candesartantreated SHRSP and WKY rats. Tubular atrophy, tubular casts and interstitial fibrosis were observed in non-treated SHRSP and occasionally in hydralazine-treated SHRSP, but not in candesartan-treated SHRSP and WKY rats. These results indicated that candesartan was superior to hydralazine as far as renal protection was concerned. 15 It has been reported that losartan 16, 17 and candesartan cilexetil [18] [19] [20] [21] [22] also protected the development of cardiac hypertrophy in spontaneously hypertensive rats (SHR), but hydralazine did not, 19, 21, 22 although it reduced BP, supporting the assumption that AT 1 receptor antagonists have protective action against cardiac hypertrophy independent of BP-lowering action. In DOCA/salt hypertensive rats losartan also inhibited cardiac hypertrophy despite not having a significant anti-hypertensive action. 23 In Dahl hypertensive rats losartan reduced stroke incidence, renal lesion and the mortality rate 24 and cardiac hypertrophy and left ventricular wall thickness, 25 despite not having a significant antihypertensive action. 24, 25 Candesartan cilexetil reduced BP and inhibited cardiac hypertrophy, proteinuria and glomerulosclerosis in this model. 26 The precise mechanism is not clear why candesartan cilexetil protected against renal injury and stroke at the dose which had no effect on BP (Figures 2 and  5) .
Lafayette 27 has reported that losartan reduced BP, glomerular transcapillary pressure and inhibited the development of proteinuria and segmental glomerular sclerosis in 5/6 nephrectomised rats. Interestingly, he also reported that a combined treatment of reserpine, hydralazine and hydrochlorothiazide had no effect on these parameters, although the combination reduced BP. These findings suggest that the effects of losartan are not attributable simply to normalisation of systemic BP. Similar renal protective effects in 5/6 nephrectomised rats have been observed in the experiments using candesartan cilexetil. 28, 29 There are some papers indicating that AT 1 receptor antagonists inhibit directly the hypertrophic and proliferative action of angiotensin II in in vitro experiments. Angiotensin II increased the expression of immediate early oncogenes, c-fos and c-myc, in cultured rat cardiomyocytes which was associated with the increase in mRNAs of endothelin-1 and endothelin-B receptor. Candesartan inhibited the expression of these genes, suggesting the involvement of endogenous endothelin-1 in angiotensin AT 1 receptor-mediated cardiac hypertrophy. The expression of the oncogenes (cfos, c-myc) was increased in vascular smooth muscle cells, which was also blocked by candesartan. 30 In cultured neonatal cardiomyocytes, angiotensin II decreased [Ca ++ ] i concentration transiently, induced c-fos-mRNA and accelerated hypertrophy. These effects were completely suppressed by candesartan. 31 In neonatal rat cardiac fibroblast, angiotensin II stimulated the synthesis of protein, DNA and RNA, which was inhibited by EXP-3174, suggesting that angiotensin II-induced cardiac hypertrophy is, in part, secondary to stimulated increases in nonmyocyte cellular growth. 32 In cultured adult rat cardiac fibroblasts, angiotensin II stimulated the mRNA expression of collagen type I and III, the major fibrillar collagens in the heart, and decreased the mRNA of collagenase, the key enzyme for interstitial collagenase degradation. Losartan abolished the gene expression of collagen and had no effect on collagenase activity. 33 Cultures of adult rat cardiac fibroblasts express AT 1 but not AT 2 receptors and angiotensin II-stimulated increase in [Ca ++ ] i and several growth-related metabolic events including c-fos gene expression and increased synthesis of DNA, RNA and protein and collagen type I synthesis were blocked by losartan. 34 In the experiments using cultured rat or human mesangial cells, losartan inhibited the angiotensin II-stimulated hypertrophy [35] [36] [37] and proliferation 36, 37 of the mesangial cells. Similar results have been reported in the experiments using cultured vascular smooth muscle cells; namely, angiotensin II with or without PDGF or EGF stimulated the proliferation of cultured smooth muscle cells, which was inhibited by losartan [38] [39] [40] or candesartan. 41 Based on the results shown in this paper and the findings reported in the literature, it is summarised that angiotensin AT 1 receptor antagonists protect against end-organ damage which is produced in the models of rats. The protective effects do not necessarily depend on the BP-lowering effects. Inhibition of TGF-␤1 and extracellular matrix component (TGF-␤1 and collagen type I, III and IV) production may be partially involved in this protective action. 
